Field support / Product specialist

Field support / Product specialist 

Our company
Polyganics is an innovative medical technology company. We develop, manufacture and commercialize worldwide, innovative bioresorbable devices to facilitate tissue repair and regeneration after surgery. We adapt our versatile polymers for different applications, improving surgical outcome and patient recovery.

The job
You will be our “guide” for medical specialists and the sales reps of our distributors who are starting to work with our products. On the other hand you will gather information from them and in this way obtain input to help us increase the clinical and economical added value of our products.
You will conduct training modules and presentations for doctors, nurses and for the sales reps of our distributors and you will provide clinical product training and assistance. You will also be involved in clinical support on study sites and support surgeons assisting our clinical department. This full-time position demands intensive travelling within Europe and the US.

Your profile
You are a product specialist, preferably with several years experience as surgery assistant or nurse, with a specialism in neurosurgery being a pre. You can train professionals, and have excellent educational skills
You have a Bachelor degree / equivalent education and several years of work experience.
Work experience in the medical device industry is necessary.
You are fluent in English and another European language and maybe also in Dutch.
You have very pleasant and effective social skills.

Our offer
We offer a responsible, independent and challenging position in a growing organization with the opportunity to develop yourself.
Polyganics has a professional but informal working environment, a pleasant work atmosphere and almost 50 enthusiastic colleagues. We offer a competitive salary and secondary benefits.

Would you like more information?
Please contact: Raoul Beex, International sales director +31 (0)50 588 6588 or
Henne Barkema, HR, +31 (0)6 52 0616 35.

If interested, you can send your application to hrm@polyganics.com.

Vacancy Field support 2019

Headhunters need not to apply.

 

Headhunters need not to apply.

 

Polyganics Achieves Positive 3-month Follow-up Data of ENCASE I, the First Clinical Trial for LIQOSEAL®

Groningen, The Netherlands, 17 September 2019 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, has today announced positive data from its ENCASE I* clinical trial.

The ENCASE I trial is focused on the evaluation of the safety and performance of LIQOSEAL® in reducing cerebrospinal fluid (CSF) leakage following elective cranial surgery. The 3-month results of ENCASE I show the absence of CSF leakage as confirmed by MRI, no clinically significant swelling, and no device-related adverse events following surgeries that used LIQOSEAL® for dural closure. Polyganics has submitted its filing for the CE Mark of LIQOSEAL® based upon these positive data from the ENCASE I trial.

LIQOSEAL® is a safe, synthetic, easy-to-use dura sealant patch, developed using Polyganics’ proprietary bioresorbable polymer technology, already applied worldwide in multiple clinical areas. The patch is indicated for use as an adjunct to standard methods of cranial dural repair to provide a watertight closure of the dura mater and reduce CSF leakage. In vivo studies show that LIQOSEAL® also supports regeneration of the dura mater during the critical healing period, by acting as a scaffold for new fibrotic layer formation (‘neodura’).

Dr Tristan van Doormaal, Neurosurgeon at the University Hospital Zurich and University Medical Center (UMC) in Utrecht, Principal Investigator of the study and leader of the initial research project at the Brain Technology Institute (BTI) commented: “CSF leakage remains a devastating complication for neurosurgical patients. These follow-up results from ENCASE I support previous in vitro and in vivo observations and indicate that LIQOSEAL® is safe to use in patients and seemingly shows better reduction of CSF leakage over standard of care methods as referred to in clinical literature. Interestingly, the unique scaffolding characteristic of this purely synthetic resorbable product, promotes the formation of a new layer of native dura, the layer that surrounds the brain and the spinal cord and which is responsible for keeping in the cerebrospinal fluid.” He continued: “I am pleased with the submission, as CE approval will enable surgeons and patients to benefit from LIQOSEAL®’s unique properties. I look forward to further assessing LIQOSEAL®’s value in our area of surgery in the future randomized controlled study, ENCASE II.”

Rudy Mareel, CEO of Polyganics, commented: “The submission of LIQOSEAL® for CE marking is another important step as we work towards commercializing this product, which is the first in our Neurosurgery portfolio. We are very encouraged by the positive data that enabled us to file this submission. Following CE approval, we plan to launch LIQOSEAL® in a number of countries across Europe, and ultimately plan to submit the product for pre-market approval (PMA) to the US Food and Drug Administration.”

Polyganics will be present at EANS 2019 (European Association of Neurological Societies) in Dublin, 24th-28th September, at the Company booth (#56). Dr. Tristan van Doormaal will provide an overview of the development of LIQOSEAL® in an oral presentation at Poster booth 1 in the 10:00 – 10:40 am session on Friday 27th September.

 * ENCASE I: Single-arm, open-label, multi-center study to Evaluate the safety and performaNCe of DurA Sealant Patch in reducing CSF leakage following Elective cranial surgery

– ENDS –

For more information please contact:

Polyganics
Paul Roos, Chief Financial Officer
Romke Ribbels, Director Marketing & Business Development
T: +31 50 588 65 88
E: info@polyganics.com

Instinctif Partners
Dr Christelle Kerouedan / Dr Katie Duffell
T: +44 (0)20 7457 2020
E: polyganics@instinctif.com

Notes to editors

 About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

Polyganics’ portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. In the Peripheral Nerve Repair (PNR) field, the portfolio includes three marketed products: VIVOSORB® for minimizing unwanted tissue adhesions after surgery; NEUROLAC® for supporting PNR following hand surgery; and NEUROCAP® for the management of symptomatic neuromas. In the Neurosurgery and General Surgery field, products in development include a sealant for the dura membrane (LIQOSEAL®) and the Liver and Pancreas Sealant Patch.

In 2014, Polyganics sold its Ear, Nose & Throat (ENT) surgery business unit (the NASOPORE® product family including HEMOPORE®, SINUPORE® and OTOPORE® and NASOPORE-FD®) to Stryker, one of the world’s leading medical technology companies. Polyganics continues to manufacture the NASOPORE® product range for Stryker. To date, Polyganics has produced and delivered more than 5 million devices.

Polyganics is a privately held company based in Groningen, The Netherlands, a center of biomedical engineering excellence, where it has an ISO 13485-certified manufacturing facility. The company’s polymer platform technologies are protected by a broad portfolio of patents and its products have received clearance from the US FDA, CE-approval, and approval from CFDA and other international authorities.

For more information, visit: www.polyganics.com , or follow us on LinkedIn: Polyganics BV

About CSF leakage

CSF leakage is a widely recognized complication of neurosurgical procedures. It represents a significant patient burden, resulting in increased morbidity, prolonged hospital stays, possible surgical revisions, and enhanced costs.1,2 Incidence rates vary depending on age, indication, location of surgery and underlying pathology, but in total CSF leakage occurs in 4-32% of surgical cases.3,4

About ENCASE I

ENCASE I, the first-in-human trial of LIQOSEAL®, is a single-arm, open-label study evaluating the safety and performance of LIQOSEAL® in reducing CSF leakage following elective cranial surgery. 40 adult patients have been recruited at three sites across the Netherlands and Switzerland, with follow-up due to span a period of 12 months.

Details of the ENCASE I study can be found at: https://clinicaltrials.gov/ct2/show/NCT03566602

References

  1. Hutter G, von Felten S, Sailer M, Schulz M, Mariani L. Risk factors for postoperative CSF leakage after elective craniotomy and the efficacy of fleece bound tissue sealing against dural suturing alone: a randomized controlled trial. Neurosurgery. 2014. Sep; 121:724-744
  2. Grotenhuis J. Costs of postoperative cerebrospinal fluid leakage: 1-year, retrospective analysis of 412 consecutive nontrauma cases. Surg Neurol. 2005, Dec; 64(6)|:490-3
  3. Kinaci A, Algra A, Heuts S, O’Donnell D, van der Zwan A, van Doormaal T. Effectiveness of Dural Sealants in Prevention of Cerebrospinal Fluid Leakage After Craniotomy: A Systematic Review. World Neurosurg. 2018 Oct;118:368-376
  4. van Doormaal T, Kinaci A, van Thoor S, Redegeld S, Bergmann W, van der Zwan A.Usefulness of Sealants for Dural Closure: Evaluation in an In Vitro Model. Oper Neurosurg (Hagerstown). 2018 Oct 1;15(4):425-432.

 

Polyganics Builds New Facility to Continue Growth, Supported by RIG Subsidy of €3.8 Million

Groningen, The Netherlands, 10 April 2019 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, is expanding its capacity with a new facility at the Zernike Campus, Groningen, to enter a new phase of commercial and R&D growth. Polyganics has been awarded a subsidy of €3.8 million by the Regional Investment Aid Groningen (RIG) initiative to support this development.

To-date, Polyganics has enjoyed significant growth and success in manufacturing, commercialization and R&D. After selling its leading NASOPORE® portfolio to Stryker in 2014, Polyganics continues to manufacture these products. In addition, Polyganics’ proprietary Peripheral Nerve Repair (PNR) portfolio continues its international roll-out. LIQOSEAL®, the Company’s lead Neurosurgery product, has entered clinical trials, and its Liver and Pancreas Sealant Patch has achieved multiple milestones on its path to the clinic, including being granted Breakthrough Designation by the FDA.

Polyganics will build a dedicated new site, which will house its headquarters, state-of-the-art research laboratories and expanded manufacturing and packaging facilities. The purpose-built facility will provide the space to ensure that the company can continue to develop and deliver a reliable supply of bioresorbable medical devices to its customers and remain at the forefront of research and manufacturing excellence.

To support the development of this new site, Polyganics has been awarded a €3.8 million RIG subsidy. The RIG initiative was created to support innovative and sustainable companies with the aim to boost the economy and increase employment in the Eems Delta region and at the Zernike Campus. At the Zernike Campus the primary focus is on companies in the fields of energy, chemistry, life sciences and big data.

Rudy Mareel, CEO of Polyganics, commented: “With the continued increase in demand for the ENT and PNR portfolios, and a strong growth outlook for the various highly promising products in our pipeline, our move to the larger facility at the Zernike Campus is absolutely essential. We are grateful to receive a RIG subsidy to support our expansion, which will enable us to continue to do what we are doing best: providing unique bioresorbable medical devices, addressing unmet clinical needs.”

Patrick Brouns, member of the Provincial Executive of Groningen, commented: “This investment is well aligned with our strategy to enable innovation and stimulate growth in the region. Polyganics has a track record of success and it provides attractive employment opportunities. The province of Groningen is proud to support such companies, which provide and motivate ongoing investment in our region.”

Polyganics is preparing to start building by the end of 2019, with the aim to move into its new facility in 2021.

For more information please contact:

Polyganics
Paul Roos, Chief Financial Officer
Romke Ribbels, Director Marketing & Business Development
T: +31 50 588 65 88
E: info@polyganics.com

Instinctif Partners
Dr Christelle Kerouedan / Dr Katie Duffell
T: +44 (0)20 7457 2020
E: polyganics@instinctif.com

Notes to editors

About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

Polyganics’ portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. In the Peripheral Nerve Repair (PNR) field, the portfolio includes three marketed products: VIVOSORB® for minimizing unwanted tissue adhesions after surgery; NEUROLAC® for supporting PNR following hand surgery; and NEUROCAP® for the management of symptomatic neuromas. In the Neurosurgery and General Surgery field, products in development include a sealant for the dura membrane (LIQOSEAL®) and the Liver and Pancreas Sealant Patch.

In 2014, Polyganics sold its Ear, Nose & Throat (ENT) surgery business unit (the NASOPORE® product family including HEMOPORE®, SINUPORE® and OTOPORE® and NASOPORE-FD®) to Stryker, one of the world’s leading medical technology companies. Polyganics continues to manufacture the NASOPORE® product range for Stryker. To date, Polyganics has produced and delivered more than 5 million devices.

Polyganics is a privately held company based in Groningen, The Netherlands, a center of biomedical engineering excellence, where it has an ISO 13485-certified manufacturing facility. The company’s polymer platform technologies are protected by a broad portfolio of patents and its products have received clearance from the US FDA, CE-approval, and approval from CFDA and other international authorities.

For more information, visit: www.polyganics.com.

About the RIG

The Regional Investment Aid Groningen (RIG) has been set up with the aim to strengthen the regional economy and increase employment for industrial companies in the Eems Delta region and at the Zernike Science Park. In 2014, €40 million was made available by the Ministry of Economic Affairs, the Economic Board Groningen and the province of Groningen. An additional €12 million has been made available via the National Program Groningen. The RIG is managed on behalf of the province of Groningen by the Samenwerkingsverband Noord Nederland (SNN).

 

13th congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA)

13th congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA)

June, 2- June 5, 2019

Amsterdam, The Netherlands

American Association of Neurological Surgeons (AANS) – 2019 Annual Scientific Meeting

American Association of Neurological Surgeons (AANS) – 2019 Annual Scientific Meeting

April 13- April 17, 2019

San Diego, California, USA

International Federation of Societies for Surgery of the Hand (IFSSH) and International Federation of Societies for Hand Therapy (IFSHT)

International Federation of Societies for Surgery of the Hand (IFSSH) and International Federation of Societies for Hand Therapy (IFSHT)
17 – 21 Jun 2019
Berlin, Germany